A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal cyclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans (BO) in lung transplant (LT) patients.

Trial Profile

A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal cyclosporin A (L-CsA) versus aerosolised placebo in the prevention of bronchiolitis obliterans (BO) in lung transplant (LT) patients.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Bronchiolitis obliterans; Lung transplant rejection
  • Focus Therapeutic Use
  • Acronyms L-CsA-LT
  • Sponsors PARI Pharma GmbH
  • Most Recent Events

    • 03 Sep 2013 Status changed from recruiting to discontinued, according to ClinicalTrials.gov.
    • 16 Nov 2011 Planned number of patients changed from 180 to 200 as reported by European Clinical Trials Database.
    • 23 Sep 2011 Planned end date (December 2016) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top